Takeda Announces Voluntary Withdrawal of Lung Cancer Therapy
The company said on Monday it will voluntarily withdraw its lung cancer therapy from the US after it failed to meet the main goal in a late-stage study.
Source: medscape.com
Page 49 - Nsclc News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Nsclc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Nsclc Today - Breaking & Trending Today
Amgen's Late-Stage Data for Lung Cancer Drug 'Not Adequate'
The FDA staff reviewers have said Amgen's late-stage study might not be sufficient to confirm the effectiveness for its lung cancer drug, as the firm pursues a traditional nod for the treatment.
Source: medscape.com
Sacituzumab Govitecan + Pembrolizumab in 1L Metastatic Non–Small Cell Lung Cancer: Preliminary Results of the EVOKE-02 Study
Sandip P. Patel, MD, reviews data from the preliminary results of the EVOKE-02 study investigating sacituzumab govitecan plus pembrolizumab in first-line metastatic non–small cell lung cancer.
Source: onclive.com
Takeda to Voluntarily Withdraw Mobocertinib for EGFR Exon 20 Insertion+ NSCLC
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Source: onclive.com
Dr Brahmer on the Investigation of FLX475 in NSCLC
Julie Renee Brahmer, MD, discusses the investigation of FLX475 in patients with advanced non–small cell lung cancer.
Source: onclive.com